Patient-specific Escherichia coli antigens (Patient-specific E. coli antigens)

Patient-specific Escherichia coli antigens refer to a personalized therapeutic approach where antigens are derived from the specific strains of E. coli isolated from an individual patient. This strategy is primarily employed in the development of autologous vaccines intended to treat chronic or recurrent conditions such as refractory urinary tract infections (UTIs) and inflammatory bowel diseases like Crohn's disease, where specific pathobionts (e.g., Adherent-Invasive E. coli) are thought to drive pathology. By utilizing the exact antigenic profile of the patient's own colonizing bacteria—including O-antigens, H-antigens, and fimbrial proteins—the therapy aims to stimulate a highly specific immune response that standard, broad-spectrum vaccines may miss. In clinical practice, these antigens are typically harvested from patient samples, inactivated, and re-administered to prime the immune system to recognize and clear the specific offending strain. This personalized approach addresses the high degree of genetic and antigenic diversity found among E. coli strains, potentially offering a more effective solution for patients who fail conventional antibiotic or immunosuppressive therapies.

Other names

Autologous Escherichia coli antigensPatient-derived E. coli antigensStrain-specific E. coli antigensPersonalized E. coli vaccine antigens

Induction of a targeted immune response (humoral and cellular) against specific bacterial strains colonizing or infecting a patient to reduce pathogen load and chronic inflammation.